RecruitingNCT03571763

The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients

The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients: Prospective, Multi-center, Cohort Study

Sponsor

General Hospital of Shenyang Military Region

Enrollment

1,875 participants

Start Date

Aug 1, 2018

Study Type

OBSERVATIONAL

Conditions

Ischemic Stroke

Summary

The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Patient age ≥18 years;
Acute ischemic stroke patient confirmed by imaging;
Time of onset: within 3 months;
Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
Baseline SWI sequence must have at least one CMB ;
NIHSS≤10

Exclusion Criteria7

MRI contraindication;
Hemorrhagic transformation after acute Ischemic stroke;
Contraindication for antiplatelet or anticoagulation therapy;
Severe head trauma or intracranial hemorrhage occurred in the past six months;
obvious coagulopathy;
Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);
other unqualified patients judged by the investigator